Moderna SEC filings, summarized
We read every Moderna 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track MRNA in your inbox
Add Moderna to your watchlist — free, every morning.
Recent filings
Moderna President Stephen Hoge sells about $17.0M in stock
Moderna President Stephen Hoge sold 38,774 shares at $213.47 each for approximately $8.28 million, leaving him with 1,599,708 shares, and sold another 450…
Moderna Appoints Juan Andres as COO as Oncology Pipeline Expands
Moderna is creating a chief operating officer role and will appoint former executive Juan Andres to the position effective October 5, 2026, reporting to CEO…
Moderna Appoints Juan Andres as COO as Jerh Collins Retires
Moderna appointed Juan Andres as chief operating officer effective October 5, 2026, reporting to CEO Stéphane Bancel and overseeing manufacturing as the…
Moderna President Hoge sells about $11.7M in stock
Moderna President Stephen Hoge sold 40,294 shares at $144.13 each on September 14 for approximately $5.81 million, with 1,525,858 shares owned afterward. On…
Moderna CFO Mock James M sells $4.7M in stock
Moderna Chief Financial Officer James M. Mock sold 34,836 shares in two open-market transactions on Sept. 10 at $134.49 per share, for approximately $4.69…
Moderna Prices Upsized $2.6 Billion Convertible Notes Offering
Moderna priced $2.6 billion of 0.00% convertible senior notes due March 1, 2032, up from the initially proposed $2.0 billion, with closing expected…
Moderna prices $2.6 billion of convertible notes due 2032
Moderna priced $2.6 billion of 0.00% convertible senior notes due March 1, 2032, up from the initially proposed $2.0 billion, with closing expected…
Moderna Prices $2.6 Billion Convertible Notes Due 2032
Moderna priced $2.6 billion of 0.00% convertible senior notes due March 1, 2032, up from the initially proposed $2.0 billion, with closing expected…
Moderna Completes $3 Billion Convertible Notes Offering Due 2032
Moderna completed a private offering of $3.0 billion of 0.00% convertible senior notes due March 2032, including the full exercise of a $400 million…
Moderna CEO Stephane Bancel sells approximately $28.7M in stock
Stephane Bancel, Moderna’s Chief Executive Officer and director, sold 499,246 shares in four open-market transactions on August 5 at prices ranging from…
Moderna reports $145 million Q2 revenue and narrows 2026 expense outlook
Moderna reported second-quarter 2026 revenue of $145 million for the period ended June 30, up from $142 million a year earlier, while its GAAP net loss…
BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…
BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering Spikevax & infectious disease vaccine pipeline,…
Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).
Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1). Investors should review the release for any material updates. 📰 $MRNA…
Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…
Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 — press release furnished as Exhibit 99.1. 📄📈…
Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…
Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026; Exhibit 104: Inline XBRL cover page. Check…
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will not initiate review. Notice dated Feb 3, 2026;…
Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…
Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its investigational seasonal influenza vaccine mRNA-1010. Press…
Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and…
Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and 104 Cover Page Inline XBRL. Signed by CFO James M.…
Moderna filed a Current Report on Form 8‑K (2026‑01‑12): Item 7.01 incorporates Item 2.02 and Exhibit 99.1…
Moderna filed a Current Report on Form 8‑K (2026‑01‑12): Item 7.01 incorporates Item 2.02 and Exhibit 99.1 — Regulation FD disclosure was furnished, not…
Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash…
Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash equivalents & marketable securities ≈ $8.1B. Press…